Low-Dose Bone Morphogenetic Protein Use in Spinal Fusion : Rethinking Clinical Efficacy.

J Korean Neurosurg Soc · 2025 · PMC12582887 · PMID 40460855

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Impact of clinical rhBMP-2 doses on reported controversies and complications Industry-sponsored trials of Infuse TM before approval showed a trend of increasing rhBMP-2 dose over time, reflecting the prevailing philosophy that higher doses lead to better outcomes. rhBMP-2/ACS enabled volume-dependent dose control of rhBMP-2, contingent upon the degree of underfilling or overfilling.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.